OTCMKTS:AMBS Amarantus BioScience (AMBS) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free AMBS Stock Alerts $0.0002 0.00 (0.00%) (As of 03/15/2024) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0016VolumeN/AAverage Volume164,808 shsMarket Capitalization$126,082.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Amarantus BioScience alerts: Email Address Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About Amarantus BioScience Stock (OTCMKTS:AMBS)Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.Read More AMBS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMBS Stock News HeadlinesJanuary 23, 2024 | wsj.comAmarantus BioScience Holdings Inc.November 10, 2023 | morningstar.comAmarantus Bioscience Holdings Inc AMBSMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.November 5, 2023 | forbes.comIndiana University To Invest $250 Million In Bioscience And Technology InitiativesFebruary 23, 2023 | benzinga.comJord BioScience Announces Keri Carstens as Chief Executive OfficerJanuary 11, 2023 | marketwatch.comSelecta Biosciences Shares Rise 11% After Licensing Deal With Astellas PharmaSee More Headlines Receive AMBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarantus BioScience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:AMBS CUSIPN/A CIK1424812 Webwww.amarantus.com Phone(650) 862-5391Fax408-852-4427Employees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares630,410,000Free Float565,286,000Market Cap$126,082.00 OptionableNot Optionable Beta1.26 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Gerald E. Commissiong (Age 41)CEO, President & Director Dr. John Wesley Commissiong (Age 79)Chief Scientific Officer, Director & Member of Scientific Advisory Board Mr. Robert Lewis Harris (Age 80)Compliance Officer & Director Aimee BoutcherDirector of Investor RelationsDr. Ravi Kiron (Age 64)Senior Vice President of Business Development Dr. Brian E. HarveyChief Regulatory Advisor & Member of Board of AdvisorsDr. Owen GarrickCorporate AdvisorMore ExecutivesKey CompetitorsPropanc BiopharmaOTCMKTS:PPCBWellness Center USAOTCMKTS:WCUIAdhera TherapeuticsOTCMKTS:ATRXOrexigen TherapeuticsOTCMKTS:OREXQCalithera BiosciencesNASDAQ:CALAView All Competitors AMBS Stock Analysis - Frequently Asked Questions How have AMBS shares performed in 2024? Amarantus BioScience's stock was trading at $0.0005 at the start of the year. Since then, AMBS shares have decreased by 60.0% and is now trading at $0.0002. View the best growth stocks for 2024 here. What other stocks do shareholders of Amarantus BioScience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarantus BioScience investors own include CenterPoint Energy (CNP), Adient (ADNT), Everbridge (EVBG), Ford Motor (F), Kellanova (K), Kraft Heinz (KHC), Kratos Defense & Security Solutions (KTOS), MetLife (MET), NVIDIA (NVDA) and AT&T (T). How do I buy shares of Amarantus BioScience? Shares of AMBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AMBS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarantus BioScience Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.